Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07346404 | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma(RUBIKID) | not yet recruiting | Phase 2 | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07338981 | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | not yet recruiting | Phase 3 | 142 | Guliz OzgunOTHER |
| 1 |
| Jan 14, 2026 |
| clinicaltrials |
| NCT07324876 | A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) | not yet recruiting | — | 860 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07304492 | AI for Renal Tumors Using Non-Contrast CT | not yet recruiting | — | 10,000 | Fudan UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07043543 | Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)(BLADAPT) | not yet recruiting | N/A | 120 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07233668 | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC(IVE in mRCC) | not yet recruiting | N/A | 172 | Seoul National University HospitalOTHER | 0 | Dec 3, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT07203989 | The Effect of Video Calls With Family Members During Operating Room Waiting on Stress, Anxiety, and Surgical Fear in Patients Undergoing Transurethral Resection of Bladder Tumor | not yet recruiting | N/A | 124 | Bitlis Eren UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204301 | Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study(Flexi-comfort) | not yet recruiting | N/A | 378 | Western University, CanadaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204496 | A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer(γδ-T-BLADDER) | not yet recruiting | — | 20 | Shanghai 10th People's HospitalOTHER | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer(No Acronym) | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT07140588 | Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.(NR-RC) | not yet recruiting | N/A | 10 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT07125924 | Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer | not yet recruiting | N/A | 54 | National Cancer Center, KoreaOTHER_GOV | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07113977 | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy | not yet recruiting | Early Phase 1 | 30 | Wei GuanOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT06880939 | Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects | not yet recruiting | N/A | 210 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07065825 | Tumor Rupture During Robotic Partial Nephrectomy(RUPTURE) | not yet recruiting | — | 100 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07053722 | Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy | not yet recruiting | — | 30 | Peking University First HospitalOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07053735 | An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer | not yet recruiting | Phase 1 | 30 | Peking University First HospitalOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT06994078 | Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors | not yet recruiting | N/A | 56 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06982690 | Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial | not yet recruiting | N/A | 370 | National Taiwan University HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06973798 | The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Function After Partial Nephrectomy | not yet recruiting | N/A | 40 | Luo YapingOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06960174 | Virtual Renality: Assessing the Impact of Virtual Reality on Preoperative Planning in Renal Cancer Surgery | not yet recruiting | N/A | 70 | St. Antonius HospitalOTHER | 0 | May 7, 2025 | clinicaltrials |
| NCT06957561 | Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer(DIVON) | not yet recruiting | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06870279 | A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC | not yet recruiting | Phase 1 | 28 | RenJi HospitalOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT06912672 | Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma(UMT-UC) | not yet recruiting | — | 1,500 | Shanghai Epiprobe Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 8, 2025 | clinicaltrials |
| NCT06880757 | 177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.(FAUNUS) | not yet recruiting | Phase 2 | 10 | Ankara UniversityOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT06364904 | A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | not yet recruiting | Phase 3 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06798246 | HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study | not yet recruiting | — | 200 | Peking University First HospitalOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06773377 | Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma | not yet recruiting | — | 77 | Assiut UniversityOTHER | 0 | Jan 14, 2025 | clinicaltrials |
| NCT06762925 | Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment | not yet recruiting | — | 450 | Xijing HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06751667 | Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer(LIBERO) | not yet recruiting | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06717009 | A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors. | not yet recruiting | N/A | 350 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06694649 | Better in Better Out Cystectomy.(BIBOCYS-1) | not yet recruiting | — | 100 | Ziekenhuis Oost-LimburgOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06675656 | Predictive Role of Microbiome in Patients With Urothelial Carcinoma | not yet recruiting | — | 420 | IRCCS San RaffaeleOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06585878 | A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma | not yet recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2026source: clinicaltrials